<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587574</url>
  </required_header>
  <id_info>
    <org_study_id>488/2007</org_study_id>
    <secondary_id>EK Nr 488/2007</secondary_id>
    <nct_id>NCT00587574</nct_id>
  </id_info>
  <brief_title>Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT</brief_title>
  <official_title>Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic Hematopoietic Stem Cell Transplantation and Immunomodulatory Consequences of Chronic Graft-Versus-Host Disease and Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic cell transplantation offers high cure rates for patients with&#xD;
      hematological and oncological diseases. Graft-versus-host disease (attack of donor's white&#xD;
      blood cells on patient's tissues) is a serious complication also affecting the patient's&#xD;
      immune system. Therefore, patients in the early phase after allogeneic cell transplantation&#xD;
      are at high risk for severe infectious complications. So far, no predictive biomarkers for&#xD;
      the development of the chronic form of graft-versus-host disease are available. By analysing&#xD;
      serially immune cell populations of the peripheral blood we will investigate whether certain&#xD;
      subsets of cells are associated with development of chronic graft-versus-host disease. In&#xD;
      addition, the patients' immune regeneration will be evaluated by serial analyses of&#xD;
      peripheral blood immune cell populations 3 months to 2 years after allogeneic cell&#xD;
      transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of perturbed B cell homeostasis with chronic graft-versus-host disease activity of immune system</measure>
    <time_frame>October 2007 until December 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference of time-dependent pattern of immune reconstitution after allogeneic cell transplantation between patients with and without chronic graft-versus-host disease</measure>
    <time_frame>October 2010 until December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare number of clinically defined bacterial, viral and fungal infectious episodes between patients with and without chronic graft-versus-host disease</measure>
    <time_frame>October 2007 until December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the number of circulating T, DC, NK subsets in patients with and without chronic GVHD to identify their respective role in development and prolongation of chronic GVHD</measure>
    <time_frame>October 2007 until December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the impact of different immunosuppressive/immunomodulatory treatments for chronic GVHD on various immune cell populations</measure>
    <time_frame>October 2007 until December 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the chimerism of antigen-presenting cells in circulation and tissue specimens and correlate it with occurrence of chronic GVHD</measure>
    <time_frame>October 2007 until December 2010</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Allogeneic Hematopoietic Cell Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <description>Chronic graft-versus-host disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <description>No chronic graft-versus-host disease</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood mononuclear cells as cell pellets and DNA, plasma and serum samples, tissue&#xD;
      biopsy samples, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        all consecutive patients after allogeneic hematopoietic cell transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Receiving grafts from either HLA-identical sibling donors or HLA-matched unrelated&#xD;
             donors&#xD;
&#xD;
          -  Receiving grafts from HLA-mismatched sibling donors or HLA-mismatched unrelated donors&#xD;
&#xD;
          -  Receiving either bone marrow, peripheral blood stem cells or cord blood grafts&#xD;
&#xD;
          -  Alive on day 100 after transplant&#xD;
&#xD;
          -  Age 18 years or above&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lymphocytopenia not allowing immunophenotyping&#xD;
&#xD;
          -  Treatment with rituximab after HSCT until study entry&#xD;
&#xD;
          -  Hepatitis B and C, HIV infection&#xD;
&#xD;
          -  Secondary posttransplant malignancies including EBV-lymphoproliferative disease&#xD;
&#xD;
          -  Karnofsky score of 30 or below&#xD;
&#xD;
          -  Absence of informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hildegard T Greinix, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hildegard T Greinix, Professor</last_name>
    <phone>+43140400</phone>
    <phone_ext>4457</phone_ext>
    <email>hildegard.greinix@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Winfried Pickl, Professor</last_name>
    <phone>+434277</phone>
    <phone_ext>64945</phone_ext>
    <email>winfried.pickl@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hildegard T Greinix, Professor</last_name>
      <phone>+43140400</phone>
      <phone_ext>4457</phone_ext>
      <email>hildegard.greinix@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Hildegard T Greinix, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusions Prague</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>January 4, 2008</last_update_submitted>
  <last_update_submitted_qc>January 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2008</last_update_posted>
  <responsible_party>
    <name_title>Christoph Zielinski, Professor</name_title>
    <organization>Medical University of Vienna</organization>
  </responsible_party>
  <keyword>chronic graft-versus-host disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

